PRCT vs. SNN, SOLV, PEN, STVN, GKOS, IRTC, NARI, TMDX, BLCO, and SLNO
Should you be buying PROCEPT BioRobotics stock or one of its competitors? The main competitors of PROCEPT BioRobotics include Smith & Nephew SNATS (SNN), Solventum (SOLV), Penumbra (PEN), Stevanato Group (STVN), Glaukos (GKOS), iRhythm Technologies (IRTC), Inari Medical (NARI), TransMedics Group (TMDX), Bausch + Lomb (BLCO), and Soleno Therapeutics (SLNO). These companies are all part of the "medical equipment" industry.
PROCEPT BioRobotics vs. Its Competitors
PROCEPT BioRobotics (NASDAQ:PRCT) and Smith & Nephew SNATS (NYSE:SNN) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership, earnings and media sentiment.
In the previous week, PROCEPT BioRobotics had 3 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 4 mentions for PROCEPT BioRobotics and 1 mentions for Smith & Nephew SNATS. Smith & Nephew SNATS's average media sentiment score of 1.43 beat PROCEPT BioRobotics' score of 0.49 indicating that Smith & Nephew SNATS is being referred to more favorably in the news media.
89.5% of PROCEPT BioRobotics shares are held by institutional investors. Comparatively, 25.6% of Smith & Nephew SNATS shares are held by institutional investors. 6.6% of PROCEPT BioRobotics shares are held by insiders. Comparatively, 1.0% of Smith & Nephew SNATS shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
PROCEPT BioRobotics has a beta of 1.07, meaning that its stock price is 7% more volatile than the S&P 500. Comparatively, Smith & Nephew SNATS has a beta of 0.69, meaning that its stock price is 31% less volatile than the S&P 500.
PROCEPT BioRobotics currently has a consensus target price of $90.00, indicating a potential upside of 52.54%. Smith & Nephew SNATS has a consensus target price of $28.00, indicating a potential downside of 7.47%. Given PROCEPT BioRobotics' stronger consensus rating and higher possible upside, research analysts plainly believe PROCEPT BioRobotics is more favorable than Smith & Nephew SNATS.
Smith & Nephew SNATS has higher revenue and earnings than PROCEPT BioRobotics. PROCEPT BioRobotics is trading at a lower price-to-earnings ratio than Smith & Nephew SNATS, indicating that it is currently the more affordable of the two stocks.
Smith & Nephew SNATS has a net margin of 0.00% compared to PROCEPT BioRobotics' net margin of -36.20%. Smith & Nephew SNATS's return on equity of 0.00% beat PROCEPT BioRobotics' return on equity.
Summary
PROCEPT BioRobotics and Smith & Nephew SNATS tied by winning 8 of the 16 factors compared between the two stocks.
Get PROCEPT BioRobotics News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRCT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding PRCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
PROCEPT BioRobotics Competitors List
Related Companies and Tools
This page (NASDAQ:PRCT) was last updated on 7/4/2025 by MarketBeat.com Staff
Free PRCT Stock Alerts